Baxter International (NYSE:BAX) Issues Quarterly Earnings Results

Baxter International (NYSE:BAX - Get Free Report) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.52 by $0.06, Zacks reports. Baxter International had a net margin of 0.77% and a return on equity of 18.30%. The company had revenue of $2.75 billion for the quarter, compared to analysts' expectations of $2.67 billion. Baxter International updated its FY 2025 guidance to 2.450-2.550 EPS and its Q1 2025 guidance to 0.470-0.500 EPS.

Baxter International Trading Up 1.3 %

Shares of NYSE BAX traded up $0.43 during mid-day trading on Friday, hitting $33.87. The stock had a trading volume of 7,264,381 shares, compared to its average volume of 4,927,193. The business has a 50 day moving average price of $30.65 and a two-hundred day moving average price of $34.14. Baxter International has a 1 year low of $28.33 and a 1 year high of $44.01. The firm has a market cap of $17.29 billion, a P/E ratio of 169.33, a price-to-earnings-growth ratio of 9.83 and a beta of 0.61. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43.

Baxter International Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 2.01%. The ex-dividend date is Friday, February 28th. Baxter International's payout ratio is presently 340.02%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on BAX shares. Stifel Nicolaus reduced their price target on Baxter International from $46.00 to $38.00 and set a "buy" rating for the company in a research report on Monday, November 11th. Citigroup decreased their price target on shares of Baxter International from $37.00 to $35.00 and set a "neutral" rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. dropped their price objective on Baxter International from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Friday. Barclays initiated coverage on Baxter International in a report on Thursday. They issued an "overweight" rating and a $39.00 price target on the stock. Finally, StockNews.com downgraded Baxter International from a "buy" rating to a "hold" rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, Baxter International currently has an average rating of "Hold" and an average target price of $38.80.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.